Opinions of Turkish Hereditary Angioedema Patients Regarding the Use of C1 Inhibitor Concentrate in the Treatment of Acute Attacks

Objective: No data exists about the perceptions of Turkish hereditary angioedema patients regarding the use of C1 inhibitor concentrate that has been used in the treatment of acute attacks for the last 7 years. Our aim was to evaluate patient opinions about the C1 inhibitor (C1-inh) concentrate and determine the level of satisfaction with this drug. Materials and Methods: Fifty-seven hereditary angioedema (HAE) patients who used C1-inh concentrate for their angioedema attacks were asked to complete a questionnaire which contained various questions related to demographic information, clinical features, and experiences with C1-inh concentrate use. Results: Sixty-five % of the patients were female and 94.7% of the patients had type 1 HAE. The mean curent age and age of diagnosis were 38.11±12.6 and 29.95±13.85 years, respectively. Thirteen patients did not have a family history. Forty patients were under prophylaxis (danazol n=39, tranexamic acid= 1). The mean duration of the C1-inh concentrate usage was 4.07±1.76 years. The patients had taken this drug 6 times over the past year on average. All patients stated that they experienced difficulties during injections with this medication in the emergency units due to a lack of awareness by health care professionals regarding both HAE and C1-inh concentrate. While 61.4% of the patients reported overall satisfaction about the efficacy of drug, 43.8% stated that this medication should have a more practical application; 52.6% proposed that the drug should be more accessible in hospital emergency rooms. Conclusion: Patients with HAE generally considered that C1-inh concentrate was effective in their attacks. However, this group of patients expressed concerns related to the medical personnel’s awareness about HAE as well as access to the medication.


1. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology) Classification, diagnosis, and approach to treatment: Consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602-16.

2. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359:1027- 36.

3. Gompels MM, LockRJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 2005;139:379-94.

4. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31: 407-14.

5. Longhurst H, Cicardi M. Hereditary angioedema. Lancet 2012;379:474-81.

6. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline fort he management of hereditary Angioedema. World Allergy Organ J 2012;5:182-9.

7. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez-Traseira C, et al. Consensus statement on the diagnosis, management and the treatment of angioedema mediated by bradikynin. Part II. Treatment, follow up, and special situations. J Investig Allergol Clin Immunol 2011;21:422-41.

8. Costantino G, Casazza G, Bossi I, Duca P, Cicardi M. Long-term prophylaxis in hereditary angio-edema: A systematic review. BMJ Open 2012;2:e000524.

9. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2013;111:329-36.

10. Ucar R, Arslan S, Baran M, Caliskaner AZ. Difficulties encountered in the emergency department by patients with hereditary angioedema experiencing acute attacks. Allergy Asthma Proc 2016;37(1):72-5.

11. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B; HAWK (Hereditary Angioedema International Working Group). Evidencebased recommendations fort he therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 2012;67:147-57.

12. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations fort he management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013;1:458-67.

13. Christiansen SC, Bygum A, Banerji A, Busse P, Li H, Lumry W, et al. Before and after, the impact of available on-demand treatment for HAE. Allergy Asthma Proc 2015;36(2):145-50.

14. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: A viable, effective treatment option. Clin Exp Immunol 2007;147:11-7.

15. Craig T, Shapiro R, Vegh A, Baker JW, Bernstein JA, Busse P, et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. Allergy Rhinol 2017;8:e13-e19.

16. Lunn M, Santos C, Craig T. Cinryze as the first approved C1 inhibitor int he USA fort he treatment of hereditary angioedema: Approval, efficacy and safety. J Blood Med 2010;1:163-70.

17. Cinryze Prescribing Information. ViroPharma Incorporated. Accessed: October, 2008. Available from: http://www.cinryze. com/PDF/Cinryze_PI.pdf.

18. Berstein JA, Relan A, Harper JR, Riedl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol 2017;118(4):452-5.

19. Riedl MA, Banerji A, Busse PJ, Johnston DT, Davis-Lorton MA, Patel S, et al. Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. Ann Allergy Asthma Immunol 2017;119(1):59- 64.

20. Kesim B, Uyguner ZO, Gelincik A, et al. The Turkish hereditary angioedema pilot study (TURHAPS): The first Turkish series of hereditary angioedema. Int Arch Allergy Immunol 2011;156(4):443-50.

Kaynak Göster